ArticleInvestigational new drugs2018

Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.

Hsiu-Yu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.